arsenic trioxide has been researched along with Cancer of the Urinary Tract in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, HC; Chung, YT; Ho, IL; Hsieh, JT; Huang, KH; Kuo, KL; Lee, PY; Lin, WC; Pu, YS; Shi, CS | 1 |
| Bajorin, DF; Halabi, S; Small, E | 1 |
1 trial(s) available for arsenic trioxide and Cancer of the Urinary Tract
| Article | Year |
|---|---|
Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2009 |
1 other study(ies) available for arsenic trioxide and Cancer of the Urinary Tract
| Article | Year |
|---|---|
2-methoxyestradiol induces mitotic arrest, apoptosis, and synergistic cytotoxicity with arsenic trioxide in human urothelial carcinoma cells.
Topics: 2-Methoxyestradiol; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-Associated Death Protein; Caspases; Cell Cycle Checkpoints; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Estradiol; Female; Histones; Humans; Mitosis; Oxides; Phosphorylation; Poly(ADP-ribose) Polymerases; Urologic Neoplasms | 2013 |